BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
One Percent Rule Checklist For Safer Forex Trading Risk 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
NEW YORK, April 06, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of INSYS Therapeutics, Inc. (NASDAQ:INSY) who purchased shares between February 23, 2016 and March 15, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS' public statements were materially false and misleading at all relevant times.
Shareholders have until May 16, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/insys-therapeutics-inc.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
